Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

References

• DodickDWMigraineLancet2018391101271315133029523342
   PubMed Web of Science ®Google Scholar
• LiptonRBSilbersteinSDEpisodic and chronic migraine headache: breaking down barriers to optimal treatment and preventionHeadache201555Suppl 2103122 quiz 123–12625662743
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS)The International Classification of Headache Disorders, 3rd ednCephalalgia20183811211
   PubMed Web of Science ®Google Scholar
• MerikangasKRContributions of epidemiology to our understanding of migraineHeadache201353223024623432441
   PubMed Web of Science ®Google Scholar
• GBD 2015 Disease and Injury Incidence and Prevalence CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet2016388100531545160227733282
   PubMed Web of Science ®Google Scholar
• GBD 2016 Disease and Injury Incidence and Prevalence CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016Lancet2017390101001211125928919117
   PubMed Web of Science ®Google Scholar
• LiptonRBBigalMEDiamondMMigraine prevalence, disease burden, and the need for preventive therapyNeurology200768534334917261680
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO)Atlas of headache disorders and resources in the world 2011: a collaborative project of World Health Organization and lifting the burden2011 Available from: http://www.who.int/mental_health/management/who_atlas_headache_disorders.pdfAccessed April 17, 2018
   Google Scholar
• WorthingtonIPringsheimTGawelMJCanadian Headache Society Guideline: acute drug therapy for migraine headacheCan J Neurol Sci2013405 Suppl 3S1S3
   PubMed Web of Science ®Google Scholar
• FreitagFGSchloemerFMedical management of adult headacheOtolaryngol Clin North Am201447222123724680490
   PubMed Web of Science ®Google Scholar
• WeatherallMWThe diagnosis and treatment of chronic migraineTher Adv Chronic Dis20156311512325954496
   PubMed Web of Science ®Google Scholar
• Lanteri-MinetMEconomic burden and costs of chronic migraineCurr Pain Headache Rep201418138524338699
   PubMed Web of Science ®Google Scholar
• ValadeDLucasCCalvelLMigraine diagnosis and management in general emergency departments in FranceCephalalgia201131447148020670996
   PubMed Web of Science ®Google Scholar
• FriedmanBWManaging migraineAnn Emerg Med201769220220727510942
   PubMed Web of Science ®Google Scholar
• BlumenfeldAMVaronSFWilcoxTKDisability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)Cephalalgia201131330131520813784
   PubMed Web of Science ®Google Scholar
• SchwedtTJChronic migraineBMJ2014348g141624662044
   PubMed Web of Science ®Google Scholar
• PikeJMutebiAShahNFactors associated with a history of failure and switching migraine prophylaxis treatment: an analysis of clinical practice data from the United States, Germany, France, and JapanValue Health2016193A68
   Web of Science ®Google Scholar
• RizzoliPPreventive pharmacotherapy in migraineHeadache201454236436924261479
   PubMed Web of Science ®Google Scholar
• VanderpluymJEvansRWStarlingAJLong-term use and safety of migraine preventive medicationsHeadache20165681335134327477594
   PubMed Web of Science ®Google Scholar
• HeppZDodickDWVaronSFPersistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysisCephalalgia201737547048527837173
   PubMed Web of Science ®Google Scholar
• BlumenfeldAMBloudekLMBeckerWJPatterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)Headache201353464465523458496
   PubMed Web of Science ®Google Scholar
• BergerABloudekLMVaronSFOsterGAdherence with migraine prophylaxis in clinical practicePain Pract201212754154922300068
   PubMed Web of Science ®Google Scholar
• WoolleyJMBonafedeMMMaieseBALenzRAMigraine prophylaxis and acute treatment patterns among commercially insured patients in the United StatesHeadache20175791399140828842990
   PubMed Web of Science ®Google Scholar
• HeppZDodickDWVaronSFGillardPHansenRNDevineEBAdherence to oral migraine-preventive medications among patients with chronic migraineCephalalgia201535647848825164920
   PubMed Web of Science ®Google Scholar
• BigalMELiptonRBExcessive acute migraine medication use and migraine progressionNeurology200871221821182819029522
   PubMed Web of Science ®Google Scholar
• LiptonRBSerranoDNicholsonRABuseDCRunkenMCReedMLImpact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) studyHeadache201353101548156323992516
   PubMed Web of Science ®Google Scholar
• KatsaravaZBuseDCManackANLiptonRBDefining the differences between episodic migraine and chronic migraineCurr Pain Headache Rep2012161869222083262
   PubMed Web of Science ®Google Scholar
• Abu BakarNTanprawateSLambruGTorkamaniMJahanshahiMMatharuMQuality of life in primary headache disorders: a reviewCephalalgia2016361679125888584
   PubMed Web of Science ®Google Scholar
• MessaliASandersonJCBlumenfeldAMDirect and indirect costs of chronic and episodic migraine in the United States: a web-based surveyHeadache201656230632226833083
   PubMed Web of Science ®Google Scholar
• ShahAMBendtsenLZeebergPJensenRHReduction of medication costs after detoxification for medication-overuse headacheHeadache201353466567223278344
   PubMed Web of Science ®Google Scholar
• TsoARGoadsbyPJAnti-CGRP monoclonal antibodies: the next era of migraine prevention?Curr Treat Options Neurol20171982728653227
   PubMed Web of Science ®Google Scholar
• DodickDWGoadsbyPJSpieringsELSchererJCSweeneySPGrayzelDSSafety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyLancet Neurol201413988589225127173
   PubMed Web of Science ®Google Scholar
• SkljarevskiVOakesTMZhangQEffect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trialJAMA Neurol201875218719329255900
   PubMed Web of Science ®Google Scholar
• SkljarevskiVMatharuMMillenBAOssipovMHKimBKYangJYEfficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trialCephalalgia20183881442145429848108
   PubMed Web of Science ®Google Scholar
• StaufferVLDodickDWZhangQCarterJNAilaniJConleyRREvaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trialJAMA Neurol20187591080108829813147
   PubMed Web of Science ®Google Scholar
• DetkeHWangSSkljarevskiVA phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN Study. PO-01-195Cephalalgia201737IS31929067828
   PubMedGoogle Scholar
• StaufferVLSidesRCamporealeASkljarevskiVAhlJAuroraSKA Phase 3, long-term, open-label safety study of self-administered galcanezumab injections in patients with migraine. (PO-01-184)Cephalalgia201737IS31929067828
   PubMedGoogle Scholar
• Headache Classification Committee of the International Headache SocietyThe International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia201333962980823771276
   PubMed Web of Science ®Google Scholar
• KalaliAPatient satisfaction with, and acceptability of, atypical antipsychoticsCurr Med Res Opin199915213513710494497
   PubMed Web of Science ®Google Scholar
• WuJHughesMDHudsonMFWagnerPJAntimigraine medication use and associated health care costs in employed patientsJ Headache Pain201213212112722127427
   PubMed Web of Science ®Google Scholar
• PeresMFSilbersteinSMoreiraFPatients’ preference for migraine preventive therapyHeadache200747454054517445103
   PubMed Web of Science ®Google Scholar
• HeppZBloudekLMVaronSFSystematic review of migraine prophylaxis adherence and persistenceJ Manag Care Pharm2014201223324372457
   PubMed Web of Science ®Google Scholar
• YaldoAZWertzDARupnowMFQuimboRMPersistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care settingClin Ther200830122452246019167603
   PubMed Web of Science ®Google Scholar
• BonafedeMSapraSTepperSJCappellKADesaiPHealthcare costs and utilization and medication treatment patterns among migraine patients: a retrospective analysis. PS58Headache201757 S3. Special Issue: Program Abstracts: The 59th Annual American Headache Society Meeting11322628591458
   PubMed Web of Science ®Google Scholar
• BhandariAWagnerTSelf-reported utilization of health care services: improving measurement and accuracyMed Care Res Rev200663221723516595412
   PubMed Web of Science ®Google Scholar
• RitterPLStewartALKaymazHSobelDSBlockDALorigKRSelf-reports of health care utilization compared to provider recordsJ Clin Epidemiol200154213614111166528
   PubMed Web of Science ®Google Scholar